Skip to content

MDMA: all studies

Page 47 of 347: studies 461 to 470 of 3,461, newest first. Back to the MDMA overview

Research

MDMA for the Treatment of Negative Symptoms in Schizophrenia

Journal of Clinical Medicine June 7, 2022 Mitchell Arnovitz, Andrew Spitzberg, Ashkhan J. Davani et al. 29 citations

The profound economic burden of schizophrenia is due, in part, to the negative symptoms of the disease, which can severely limit daily functioning. There is much debate in the field regarding their measurement and classification and there are no FDA-approved treatments for negative symptoms despite an abundance of research. 3,4-Methylenedioxy methamphetamine (MDMA) is a schedule I substance...

DOI: 10.3390/jcm11123255 (opens in new tab) MDMA Schizophrenia object-oriented programming Methamphetamine

Prelimbic medial prefrontal cortex has bidirectional control over the expression of behavioral sensitization to 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) depending on the context of drug administration.

Neuroscience Letters June 4, 2022 Jacob A. Plocinski, Kevin T. Ball

Behavioral sensitization to MDMA is observed in the vast majority of rats if tested in the same environment in which previous MDMA exposure occurred, but not if tested in a novel, unpaired context. Previous studies have revealed a critical role for the prelimbic region of medial prefrontal cortex (PL) in the expression of sensitization to MDMA, but these studies assessed sensitization only in...

Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (“Ecstasy”) induced cytoskeletal damage

Journal of Neural Transmission June 1, 2022 Francesco Bavato, Serena Stamatakos, C. M. Yde Ohki et al.

Abstract3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) use has been linked to persistent alterations of the brain serotonergic (5-HT) system in animal and human studies, but the molecular underpinnings are still unclear. Cytoskeletal structures such as neurofilament light chain (NfL) are promising markers of drug-induced brain toxicity and may be involved in MDMA neurotoxicity. The...

Methylenedioxymethamphetamine-assisted Psychotherapy For Posttraumatic Stress Disorder: A Review

European Psychiatry June 1, 2022 J. Sá Couto, B. Da Luz, J. Rodrigues et al.

IntroductionPosttraumatic stress disorder (PTSD) is a psychiatric condition which can be developed following traumatic experience. Treatment guidelines have long considered psychotherapy as a first line treatment. Despite that, PTSD remains an illness with high rates of comorbidity. Therefore, exploring novel therapies is of utmost importance.ObjectivesClarifying methylenedioxymethamphetamine...

MDMA-Assisted Therapy for Treatment-Resistant Posttraumatic Stress Disorder (PTSD) – One step further toward a patient-centered treatment pathway

European Psychiatry June 1, 2022 S. Pratas Penedos, M.j. Freire, I. Fonseca et al.

IntroductionPTSD is a chronic, debilitating condition with limited treatment efficacy. Accessing traumatic memories often leads to overwhelming distress, impacting treatment process. Current approved pharmacological treatments have exhibited small to moderate effects when compared with placebo. Evidence suggests 3,4,-methylene-dioxymethamphetamine(MDMA)-assisted psychotherapy as a viable option...

Evidence for altered neural activity patterns after MDMA-assisted therapy in adults with chronic and severe post-traumatic stress disorder: a pilot study

medRxiv May 27, 2022 S. P. Singleton, J. B. Wang, M. Mithoefer et al. preprint

3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to facilitate the therapeutic process, in part, by decreasing fear response during fear memory processing while increasing extinction learning retention. The acute administration of MDMA in healthy controls modifies...

A review on the mitochondrial toxicity of “ecstasy” (3,4-methylenedioxymethamphetamine, MDMA)

Current Research in Toxicology May 27, 2022 João Paulo Capela, Félix Dias Carvalho 17 citations

3,4-Methylenedioxymethamphetamine (MDMA or “ecstasy”) is a drug of abuse used by millions worldwide. MDMA human abuse and dependence is well described, but addictive properties are not always consistent among studies. This amphetamine is a substrate type releaser, binding to monoamine transporters, leading to a pronounced release of serotonin and noradrenaline and to a minor extent dopamine....

DOI: 10.1016/j.crtox.2022.100075 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Mitochondrial toxicity Mitochondrial membrane potential Mitochondrial trafficking +2

Toward a New Science of Psychedelic Social Psychology: The Effects of MDMA (Ecstasy) on Social Connection

Perspectives on Psychological Science May 10, 2022 Sonja Lyubomirsky 27 citations

Psychedelic science has generated hundreds of compelling published studies yet with relatively little impact on mainstream psychology. I propose that social psychologists have much to gain by incorporating psychoactive substances into their research programs. Here I use (±)-3,4-methylenedioxymethamphetamine (MDMA) as an example because of its documented ability in experiments and clinical...

Allosteric Binding of MDMA to the Human Serotonin Transporter (hSERT) via Ensemble Binding Space Analysis with ΔG Calculations, Induced Fit Docking and Monte Carlo Simulations.

Molecules May 6, 2022 Ángel A Islas, Thomas Scior

Despite the recent promising results of MDMA (3,4-methylenedioxy-methamphetamine) as a psychotherapeutic agent and its history of misuse, little is known about its molecular mode of action. MDMA enhances monoaminergic neurotransmission in the brain and its valuable psychoactive effects are associated to a dual action on the 5-HT transporter (SERT). This drug inhibits the reuptake of 5-HT...

MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats

Translational Psychiatry May 3, 2022 Shira Arluk, Michael A. Matar, Lior Carmi et al. 19 citations

AbstractMDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, combined with psychotherapy has demonstrated efficacy for the treatment of chronic posttraumatic stress disorder (PTSD) patients. This controlled prospective study aimed to assess the bio-behavioral underpinnings of MDMA in a translational model of PTSD. Rats exposed to predator-scent stress (PSS) were...